Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class E basic helix-loop-helix protein 41 (BHLHE41) is a nuclear transcriptional repressor and member of the bHLH protein superfamily, functioning predominantly through dimerization and binding E-box elements in DNA to regulate gene expression. It modulates differentiation, circadian rhythms, DNA repair, cell cycle, apoptosis, and immune responses. BHLHE41 acts as either a tumor suppressor or oncogene depending on tissue context and is implicated in the biology of several cancers and hematological malignancies, as well as rare familial sleep phenotypes. Owing to its central regulatory role, dysregulation of BHLHE41 can contribute to oncogenesis and is under investigation as both a potential biomarker and therapeutic target. No approved drugs directly target BHLHE41, and its complex, sometimes opposing, functions in physiology and disease represent ongoing challenges for therapeutic exploitation[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Class E basic helix-loop-helix protein 41 (BHLHE41).